Logo (WIPO, 19.08.2020)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke wurde als Bildmarke am 19.08.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Armillarsphären, Planetarien, astronomische Umlaufbahnen, Atommodelle, molekulare Modelle #Farben #Atomare Modelle, molekulare Modelle, Darstellungen von menschlichen, tierischen oder pflanzlichen Zellen #Zwei vorherrschende Farben
| Markenform | Bildmarke |
| Aktenzeichen | 1562218 |
| Länder | 
|
| Basismarke |
Nr. 88829932,
11. März 2020
|
| Anmeldedatum | 19. August 2020 |
| Ablaufdatum | 19. August 2030 |
Markeninhaber
215 First Street
Cambridge MA 02142
US
Cambridge MA 02142
US
Markenvertreter
250 West 55th Street
New York NY 10019-9710
US
Waren und Dienstleistungen
01
Chemical compounds and additives for use in pharmaceutical
research; chemical compounds and additives for use in the
manufacture of pharmaceuticals; diagnostic reagents for
research use
05
Pharmaceutical preparations for the treatment of
neuromuscular diseases and disorders, muscular dystrophies,
central nervous system diseases and disorders, genetic
diseases and disorders; pharmaceutical preparations based on
morpholino oligomer technology platform for the treatment of
neuromuscular diseases and disorders, muscular dystrophies,
central nervous system diseases and disorders, genetic
diseases and disorders, and for the regulation of protein
production; pharmaceutical preparations that modulate RNA
expression for the treatment of neuromuscular diseases and
disorders, muscular dystrophies, central nervous system
diseases and disorders, genetic diseases and disorders, and
for the regulation of protein production; gene therapy
products, namely, gene delivery pharmaceuticals;
pharmaceutical preparations for gene therapy, gene editing,
and genome editing; gene therapy products for the treatment
of neuromuscular diseases and disorders, muscular
dystrophies, central nervous system diseases and disorders,
genetic diseases and disorders; biological preparations for
the treatment of neuromuscular diseases and disorders,
muscular dystrophies, central nervous system diseases and
disorders, genetic diseases and disorders; viruses, viral
vectors and viral constructs for the treatment of
neuromuscular diseases and disorders, muscular dystrophies,
central nervous system diseases and disorders, genetic
diseases and disorders; pharmaceutical preparations,
biological preparations and gene therapy products in the
nature of pharmaceutical and biological preparations for the
treatment of genetic disorders and diseases
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 12. April 2023 | 2023/22 Gaz | US | RAW: Partial Ceasing Effect |
| 28. April 2022 | 2022/18 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 28. März 2022 | 2022/13 Gaz | IS | Ablehnung |
| 21. Oktober 2021 | 2021/42 Gaz | JP | Ablehnung |
| 20. Oktober 2021 | 2021/42 Gaz | CH | Ablehnung |
| 30. September 2021 | 2021/39 Gaz | NO | Ablehnung |
| 21. September 2021 | 2021/38 Gaz | BR | Ablehnung |
| 15. April 2021 | 2021/15 Gaz | EM | Ablehnung |
| 31. März 2021 | 2021/13 Gaz | GB | Ablehnung |
| 19. August 2020 | 2020/46 Gaz | US | Eintragung |
ID: 141562218